Clinical Trial Update: Use of CXCL9 as a Biomarker of Acthar Efficacy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating CXCL9 as a biomarker of Acthar efficacy in sarcoidosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoidosis

Drugs mentioned

• Acthar (repository corticotropin injection)

Snippet

Sponsor: University of California, San Francisco | Conditions: Sarcoidosis | Phase 4 | Status: RECRUITING